Raptor Announces Clinical Results With RP103 in Huntington's Disease Phase 2/3 Trial
20 févr. 2014 07h00 HE
|
Raptor Pharmaceutical Inc
18 Month Clinical Results Showed Significantly Slower Progression of Total Motor Score in RP103 Treated Patients Without Tetrabenazine
Conference Call and Webcast Today at 8:30 a.m. EST
NOVATO,...